Attached files

file filename
EX-3.1 - EXHIBIT 3.1 - CardioGenics Holdings Inc.v323624_ex3-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934 

 

Date of report (Date of earliest event reported): September 14, 2012 (September 10, 2012)

 

CardioGenics Holdings Inc. 

(Exact Name of Registrant as Specified in its Charter)

 

Nevada 000-28761 88-0380546
     

(State or other jurisdiction of

incorporation)

(Commission File Number) (I.R.S. Employer Identification)

 

 

6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8 

(Address of Principal Executive Offices)(Zip Code)

Registrant’s telephone number, including area code: 905.673.8501

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

TABLE OF CONTENTS

  

 
Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year
 
Item 9.01 Financial Statements and Exhibits
 
SIGNATURE
 

 

 
 

 

Item 5.03 – Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year

 

On September 10, 2012, our Board of Directors (the “Board”) amended Article I, Section .01 of our By-Laws to provide the Board with full discretion to set the date of our Annual Meeting.

 

The foregoing description is qualified in its entirety by reference to the amendment approved by the Board as contained in the Amendment to By-Laws of CardioGenics Holdings Inc., effective September 10, 2012, a copy of which is attached hereto and incorporated herein as Exhibit 3.1 to this Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

3.1 Amendment to By-Laws of CardioGenics Holdings Inc. dated September 10, 2012

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  CARDIOGENICS HOLDINGS INC.
     
     
  By: /s/ Yahia Gawad
    Name: Yahia Gawad
    Title: Chief Executive Officer

 

Dated: September 14, 2012